Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial

by Alice C Eziefula, Teun Bousema, Shunmay Yeung et al.
The Lancet Infectious Diseases, Early Online Publication, 13 November 2013

10 pp. 340 kB:
http://download.thelancet.com/pdfs/journals/laninf/PIIS1473309913702688.pdf

Primaquine is the only available drug that clears mature Plasmodium falciparum gametocytes in infected human hosts, thereby preventing transmission of malaria to mosquitoes. However, concerns about dose-dependent haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiencies have limited its use. The authors conclude that 0.4 mg/kg primaquine has similar gametocytocidal efficacy to the reference 0.75 mg/kg primaquine dose, but a dose of 0.1 mg/kg was inconclusive for non-inferiority. Their findings call for the prioritisation of further trials into the efficacy and safety of doses of primaquine between 0.1 mg/kg and 0.4 mg/kg in view of the potential for widespread use of the drug to block malaria transmission.

(Visited 24 times, 1 visits today)
This entry was posted in General, Malaria. Bookmark the permalink.